Capital Markets

Capital Markets

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.

Key Contacts

Meet Our Team

Areas of Focus

Expand All Collapse All

Initial Public Offerings: A Practical Guide to Going Public

Initial Public Offerings: “A Practical Guide to Going Public” is the ultimate roadmap to the IPO process. Hailed by executives, entrepreneurs, general counsel, investment bankers and venture capitalists alike as the definitive IPO guide, this comprehensive resource charts every twist and turn on the IPO journey and provides battle-tested, real-world advice on how to navigate the roadblocks.

2019 IPO Report—A Detailed IPO Market Review and Outlook



  • Initial Public Offerings – Issuers

    Representing Acacia, Aileron Therapeutics, Apellis Pharmaceuticals, Arsanis, Arvinas, Blue Apron, Casa Systems, Constellation Pharmaceuticals, Editas Medicine, EverQuote, Kala Pharmaceuticals, Spring Bank Pharmaceuticals, Stealth BioTherapeutics, Syros Pharmaceuticals and Translate Bio in initial public offerings.
  • Initial Public Offerings – Underwriters

    Representing the underwriters in the initial public offerings of Adaptimmune Therapeutics, Biotie Therapies, CarGurus, ChannelAdvisor, Entasis Therapeutics, HubSpot, Imprivata, MacroGenics, ProQR Therapeutics, Rhythm Pharmaceuticals, TCR² Therapeutics, Xeris Pharmaceuticals and Zynerba Pharmaceuticals.
  • Follow-On Public Offerings

    Representing Acacia, Achillion Phamaceuticals, Agios Pharmaceuticals, Apellis Pharmaceuticals, Argos Therapeutics, Casa Systems, Casella Waste Systems, Catabasis Pharmaceuticals, Editas Medicine, Epizyme, Franklin Street Properties, Genpact, Idera Pharmaceuticals, Infinity Pharmaceuticals, Karyopharm Therapeutics, Medtronic, Nabriva, Nightstar Therapeutics, Ocular Therapeutix, Spark Therapeutics, Tetraphase Pharmaceuticals, Thermo Fisher Scientific and Voyager Therapeutics in follow-on public offerings.
  • Rule 144A Placements

    Representing Akamai Technologies, Bottomline Technologies, Entegris, Fortive, Huntington Ingalls Industries, PTC Therapeutics, Red Hat and WEX in Rule 144A placements of convertible and senior note offerings.
  • Public Offerings of Senior Notes, Convertible Notes, Mandatory Convertible Preferred Stock and Preferred Stock

    Representing Analog Devices, Danaher, Discovery, Entegris, Federal Agricultural Mortgage Corporation, Fortive, Intercept Pharmaceuticals, Karyopharm Therapeutics, Medtronic, PerkinElmer, State Street and Thermo Fisher Scientific in public offerings of senior notes.


  • Award Text

    Ranked Among the Top Five Law Firms Handling IPOs for Issuers

    American Lawyer, Corporate Scorecard


  • Award Text

    Recognized Among the Nation's Best for Capital Markets: Derivatives

    Chambers USA


  • Award Text

    Named to the Top National Corporate Law Firms List

    Corporate Board Member

    2014, 2016, 2018

  • American Lawyer – The 2017 Corporate Scorecard report ranked WilmerHale among the top five law firms handling IPOs for issuers based on the number of transactions in 2016.
  • Best Lawyers in America – Recognized 124 WilmerHale partners for 2019, naming eleven as “Lawyers of the Year,” including David Westenberg as Boston Technology Law Lawyer of the Year. 
  • Chambers Global – Recognized 34 WilmerHale lawyers and 27 practice areas in their 2020 edition. Among those named “The Leading Global Lawyers for Business” were Mark Borden and Jay Bothwick for corporate/M&A, Robert Finkel for outsourcing, and Paul Architzel for capital markets/derivatives.
  • Chambers USA: America’s Leading Lawyers for Business – Recognized our capital markets: derivatives practice among the best in the nation in 2018–2019 and our corporate practice among the best in 2012–2017, with sources saying that WilmerHale provides “excellent service and quality advice and representation.” The 2017–2019 editions of Chambers USA also ranked WilmerHale in the following regions and practices: Massachusetts and Washington DC for Corporate/M&A; nationwide for Startups & Emerging Companies; and Massachusetts for Private Equity: Venture Capital Investment and Technology.
  • Corporate Board Member – In 2014, 2016 and 2018, WilmerHale was named to Top National Corporate Law Firms list, a comprehensive ranking of the top 25 firms in the nation. Results are based on law firm surveys and feedback from thousands of directors and general counsel.
  • Lake Whillans – The Life Sciences Law Firm Index included WilmerHale among the top three best life sciences law firms (2016, 2017), as the top firm for startup work (2017), among the top 10 deal firms (2017), the top two patent law firms (2016) and top 10 firms for thought leadership (2016).
  • Law360 – Named WilmerHale a Technology Practice Group of the Year for 2016–2019, an award recognizing the firm’s key role in the significant matters that made headlines and changed the legal landscape within the past year. 
  • Super Lawyers – Our corporate lawyers are consistently recognized as “Super Lawyers” and “Rising Stars” in multiple jurisdictions
  • U.S. News - Best Lawyers® – In the 2010–2020 “Best Law Firms” rankings, our corporate law, mergers and acquisitions and venture capital law practices were ranked in the first tier nationally and in Boston, along with our corporate law practice also being ranked in the first tier in New York and Washington DC. Our technology law practice was also ranked in the first tier in Boston and in the second tier nationally.

Insights & News